Researchers at the Max Planck Institute for Evolutionary Anthropology have addressed a longstanding challenge in CRISPR ...

Scientists at the McGovern Institute for Brain Research at MIT and the Broad Institute of MIT and Harvard have re-engineered ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

Dr. Wright brings deep experience across a wide breadth of therapeutic areas and modalities and will guide clinical ...

Researchers have engineered a compact, high-specificity IscB variant, NovaIscB, for safe, persistent in vivo epigenome ...

On May 12, 2025, the Court of Appeals for the Federal Circuit vacated-in-part and remanded a Patent Trial and Appeal Board (“PTAB”) decision in ...

Regents of the Univ. of California v. Broad Inst., Inc., No. 2022-1594, 2025 WL 1363125 (Fed. Cir. May 12, 2025) - On May 12, ...

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

BACKGROUND: Dilated cardiomyopathy (DCM) is substantially influenced by genetic factors. Sarcomere function is intricately associated with other organelles, particularly the reciprocal regulation ...